JPRN-UMIN000011217已完成2 期
Phase 2 study of BKM120 in patients with advanced esophagus cancer - BKM120 Phase 2 ESCC
ational Cancer Center Hospital East0 个研究点目标入组 41 人开始时间: 2013年7月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Prior chemotherapy within 3 weeks prior to enrollment. 2)Major Surgery or radiation therapy within 3 weeks prior to enrollment. 3)Other investigational drugs within 3 weeks prior to enrollment. 4)with the history of PI3K Inhibitor AKT Inhibitor or mTOR Inhibitor treatment. 5)With CNS metastasis. 6)Carcinomatous pleural effusion, or ascites, cardiac effusion with indication of invasive treatment. 7)Synchronous or asynchronous other cancer except carcinoma in situ or intramucosal carcinoma. 8)Any severe and / or uncontrolled medical conditions. 9)Interstitial pneumonia. 10)Positive HBs antigen,HCV antibodyor known positive HIV antibody test. 11)Chronic treatment with steroids or another immunosuppressive agent. 12)Chronic treatment with warfarin or coumarin derivatives. 13)Treatment with strong CYP3A inhibitor. 14)PHQ-9 questionnaire is 12 or more. 15)PHQ-9 No.9 concerning the possibility of suicide idea of the PHQ-9 questionnaire was answered, "1,2 or 3". 16)GAD-7 questionnaire is >=15 17)The major depressive episode, the bipolar disorder,and the obsessive compulsive disorder, schizophrenia, the unsuccessful suicide attempt, the thought of suicide or homicide are possessed or the past exists. 18)Anxiety is Gr 3 or more. 19)With mind abnormal conduction. Unstable angina Pericarditis Cardiac infarction Congestive heart failure Cardiomyopathy 20)LVFE is less than 50% 21)With abnormal cardiac conduction Serious Ventricular arrhythmias Supraventricular or tuberosity arrhythmia Abnormal cardiac conduction Other abnormal arrhythmia that uncontrolled with medicine 22)QT interval is extended, and administering the medicine to which the risk of inducing torusa-dodopoan has been received now. 23)Gastrointestinal functional disorder or digestive diseases with the possibility to influence the absorption remarkably are possessed. 24)Pt is unwilling or unable to comply with the protocol. 25)Pt is judged by the investigator. 26)Pregnancy or lactation
研究者
相似试验
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphomaMedDRA version: 16.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-DEovartis Pharma Services AG66
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractorydiffuse large B-cell lymphoma, mantle cell lymphoma and follicularlymphomaDiffuse large B-cell lymphoma, Mantle cell lymphoma and FollicularlymphomaMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-ESovartis Farmacéutica S.A.66
进行中（未招募）
不适用
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphomaDiffuse large B-cell lymphoma, Mantle cell lymphoma and Follicular lymphomaMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-ITOVARTIS FARMA66
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphomaMedDRA version: 17.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-BEovartis Pharma Services AG66
未知
3 期
Phase 3 clinical study of AK-120 in patients with herpes zosterHerpes zosterJPRN-jRCT2080220058ASAHIKASEI PHARMA CORPORATIO